Suppr超能文献

玻璃体内注射雷珠单抗联合多点全视网膜激光光凝治疗增殖性糖尿病视网膜病变患者的视网膜功能

Retinal function in eyes with proliferative diabetic retinopathy treated with intravitreal ranibizumab and multispot laser panretinal photocoagulation.

作者信息

Messias Katharina, Barroso Rafael de Montier, Jorge Rodrigo, Messias Andre

机构信息

Department of Ophthalmology, Otolaryngology and Head and Neck Surgery, Ribeirão Preto School of Medicine, Av. Bandeirantes 3900, Ribeirão Prêto, SP, 14049-900, Brazil.

出版信息

Doc Ophthalmol. 2018 Oct;137(2):121-129. doi: 10.1007/s10633-018-9655-9. Epub 2018 Sep 12.

Abstract

PURPOSE

To compare retinal function changes in eyes with proliferative diabetic retinopathy (PDR) after intravitreal ranibizumab (IVR), combined or not with conventional (ETDRS) or multispot laser panretinal (PASCAL) photocoagulation (PRP).

METHODS

This study included laser-naive PDR patients that required PRP. Eyes were randomly and prospectively assigned to receive IVR or IVR combined with PASCAL or EDTRS. PRP was performed at baseline in 1 (PASCAL) or 2 (ETDRS) sessions. In eyes with macular edema, macular short pulse grid laser was associated with IVR at baseline and IVR was repeated monthly or quarterly if neovascularization was detected on angiography. Comprehensive ophthalmological evaluations, including SD-OCT, were performed at baseline and every 4 weeks after treatment. Full-field electroretinography (ERG: extended ISCEV standard) was performed at baseline and at 12, 24 and 48 weeks.

RESULTS

IVR = 13, PASCAL = 15 and ETDRS = 15 eyes finished 48-week follow-up. There was a statistically significant BCVA improvement of 0.1-0.3 logMAR in all groups, and fluorescein angiography leakage area (FLA) reduced in 56%, 73%, and 73% from baseline for ETDRS, IVR and PASCAL, respectively, up to 48 weeks without significant differences between groups (p > 0.05). A significant a- and b-wave amplitudes reduction was observed for dark- and light-adapted ERG for ETDRS and PASCAL, but only minor dark-adapted b-wave reduction was found for IVR, up to 48 weeks. As an example, at week 48, combined response b-wave amplitude reduced in 181.5 ± 31.4 µV, 128.0 ± 27.9 µV and 82.4 ± 15.2 µV for ETDRS, PASCAL and IVR (p < 0.05 each group), respectively. No significant difference was observed between ETDRS and PASCAL for any ERG parameter.

CONCLUSIONS

IVR combined with single or multiple spot PRP causes similar retinal function impairment during 48 weeks of observation, while IVR alone seems to be similarly effective controlling FLA without changing retinal function.

摘要

目的

比较玻璃体内注射雷珠单抗(IVR)联合或不联合传统(ETDRS)或多点全视网膜(PASCAL)激光光凝(PRP)治疗增生性糖尿病视网膜病变(PDR)后眼睛的视网膜功能变化。

方法

本研究纳入了需要PRP治疗的初诊PDR患者。将患者的眼睛随机、前瞻性地分为接受IVR组或IVR联合PASCAL或ETDRS组。PRP在基线时进行1次(PASCAL)或2次(ETDRS)。对于有黄斑水肿的眼睛,在基线时将黄斑短脉冲格栅激光与IVR联合应用,如果在血管造影中检测到新生血管,则每月或每季度重复进行IVR治疗。在基线时以及治疗后每4周进行包括SD-OCT在内的全面眼科评估。在基线时以及第12、24和48周进行全视野视网膜电图(ERG:扩展的国际临床视觉电生理学会标准)检查。

结果

IVR组13只眼、PASCAL组15只眼和ETDRS组15只眼完成了48周的随访。所有组的最佳矫正视力(BCVA)均有统计学意义的改善,提高了0.1 - 0.3 logMAR,荧光素血管造影渗漏面积(FLA)在ETDRS组、IVR组和PASCAL组分别从基线下降了56%、73%和73%,直至48周,组间无显著差异(p > 0.05)。在ETDRS组和PASCAL组中,暗适应和明适应ERG的a波和b波振幅均有显著降低,但在IVR组中,仅暗适应b波有轻微降低,直至48周。例如,在第48周时,ETDRS组、PASCAL组和IVR组联合反应b波振幅分别降低了181.5±31.4 μV、128.0±27.9 μV和82.4±15.2 μV(每组p < 0.05)。在任何ERG参数方面,ETDRS组和PASCAL组之间均未观察到显著差异。

结论

在48周的观察期内,IVR联合单点或多点PRP会导致类似的视网膜功能损害,而单独使用IVR在控制FLA方面似乎同样有效,且不改变视网膜功能。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验